# Common Clinical Trial Eligibility Patterns
# Reference Guide for Trial Matching RAG System
# Last Updated: 2025-11-06

This document outlines common eligibility criteria patterns across oncology clinical trials,
organized by trial phase, treatment line, and cancer type. Used to predict trial eligibility
and improve patient-trial matching accuracy.

================================================================================
## ELIGIBILITY PATTERNS BY TRIAL PHASE
================================================================================

### PHASE 1 TRIALS (Dose Escalation / First-in-Human)
================================================================================

**Purpose:** Determine maximum tolerated dose (MTD), safety, pharmacokinetics

**Typical Inclusion Criteria:**

**Disease Requirements:**
- Advanced solid tumors (often tumor-agnostic in dose escalation)
- Refractory to standard therapy OR no standard therapy exists
- Measurable disease preferred but not always required
- Expansion cohorts: Specific tumor types

**Performance Status:**
- ECOG 0-1 (rarely ECOG 2)
- Life expectancy ≥12 weeks minimum

**Prior Treatment:**
- No limit on prior lines (can be heavily pretreated)
- Adequate washout period (typically 2-4 weeks)
- Prior investigational agents: Usually 4 weeks washout

**Organ Function (Typically More Stringent):**
- ANC ≥1.5 × 10⁹/L
- Platelets ≥100 × 10⁹/L (sometimes ≥75)
- Hemoglobin ≥9 g/dL
- Total bilirubin ≤1.5 × ULN (unless Gilbert's syndrome)
- AST/ALT ≤2.5 × ULN (≤5 × ULN if liver metastases)
- Creatinine clearance ≥50-60 mL/min
- LVEF ≥50% (for cardiotoxic agents)
- QTc <470-480 ms (for agents with QT risk)

**Brain Metastases:**
- Often EXCLUDED in dose escalation
- May be allowed in expansion if treated and stable
- Leptomeningeal disease: Usually excluded

**Typical Exclusions:**
- Active second malignancy (except skin cancers, in situ carcinomas)
- Uncontrolled intercurrent illness
- Active infection requiring IV antibiotics
- Immunocompromised patients
- Pregnant or nursing
- Unable to swallow oral medications (for oral agents)

### PHASE 2 TRIALS (Efficacy Testing)
================================================================================

**Purpose:** Assess efficacy in specific tumor types, determine response rate

**Typical Inclusion Criteria:**

**Disease Requirements:**
- Specific tumor type(s) and histology
- Measurable disease by RECIST 1.1 (usually required)
- Specific biomarker status (increasingly common)
- Disease stage: Locally advanced or metastatic

**Performance Status:**
- ECOG 0-1 (standard)
- ECOG 0-2 (sometimes allowed in later-line trials)

**Prior Treatment:**
- Specific number of prior lines (1-3 most common)
- Progression on or after prior standard therapy
- May require specific prior treatments (e.g., "platinum-refractory")

**Organ Function (Moderate Requirements):**
- ANC ≥1.5 × 10⁹/L
- Platelets ≥100 × 10⁹/L
- Hemoglobin ≥9 g/dL
- Total bilirubin ≤1.5-2 × ULN
- AST/ALT ≤3 × ULN (≤5 × ULN with liver mets)
- Creatinine clearance ≥30-50 mL/min

**Brain Metastases:**
- Treated and stable brain metastases: Often ALLOWED
- No active or growing brain lesions
- Off steroids or on stable dose
- Leptomeningeal disease: Usually excluded

**Biomarker Requirements (Increasingly Common):**
- PD-L1 expression (specific cutoffs)
- Molecular alterations (EGFR, ALK, BRAF, etc.)
- MSI-H/dMMR status
- TMB-high status

### PHASE 3 TRIALS (Confirmatory / Registration)
================================================================================

**Purpose:** Compare new treatment to standard-of-care, power for survival endpoints

**Typical Inclusion Criteria:**

**Disease Requirements:**
- Specific tumor type, stage, and histology
- Measurable disease required
- Specific biomarker enrichment (common)
- Treatment-naive in specific line (1st line) OR progression on specific regimen

**Performance Status:**
- ECOG 0-1 (strictly enforced)
- Rarely ECOG 2 included

**Prior Treatment:**
- Strictly defined number of prior lines
- No prior exposure to study drug class
- Specific prior regimens may be required/prohibited

**Organ Function (Stringent):**
- Similar to Phase 2 but more rigidly enforced
- Adequate bone marrow reserve
- Adequate hepatic and renal function
- Cardiac function within normal limits

**Brain Metastases:**
- Often excluded in 1st-line trials
- May be allowed if treated, stable, and asymptomatic
- Active brain metastases: Excluded

**Randomization Stratification Factors:**
- ECOG 0 vs 1
- Geographic region
- Biomarker status
- Number of metastatic sites
- Liver metastases present vs absent

================================================================================
## ELIGIBILITY PATTERNS BY TREATMENT LINE
================================================================================

### FIRST-LINE (Treatment-Naive) TRIALS
================================================================================

**Inclusion Criteria:**

**Treatment History:**
- No prior systemic therapy for advanced/metastatic disease
- Prior adjuvant/neoadjuvant therapy allowed if completed >6-12 months ago
- No prior therapy with same class as study drug

**Disease Characteristics:**
- Newly diagnosed advanced/metastatic disease
- Recurrent disease after curative-intent therapy
- Measurable disease required

**Performance Status:**
- ECOG 0-1 strictly required
- Good organ function required

**Brain Metastases:**
- Often excluded OR must be asymptomatic and treated
- More restrictive than later-line trials

**Biomarker Selection:**
- Increasingly required (PD-L1, MSI, genomic alterations)
- Enrichment for responsive populations

### SECOND-LINE TRIALS
================================================================================

**Inclusion Criteria:**

**Treatment History:**
- Progression during or after 1 prior line of systemic therapy
- Documented progression (radiographic or clinical)
- Adequate washout from prior therapy (2-4 weeks)

**Disease Characteristics:**
- Measurable disease preferred
- Progressive disease documented

**Performance Status:**
- ECOG 0-1 (standard)
- ECOG 0-2 (sometimes in specific populations)

**Brain Metastases:**
- Treated brain metastases commonly allowed
- Asymptomatic, stable on imaging

### THIRD-LINE AND BEYOND (Heavily Pretreated)
================================================================================

**Inclusion Criteria:**

**Treatment History:**
- ≥2 prior lines of systemic therapy
- Exhausted standard treatment options
- Progression on all prior regimens

**Disease Characteristics:**
- Measurable or evaluable disease
- Documented progression on last regimen

**Performance Status:**
- ECOG 0-2 more commonly allowed
- Recognizing heavily pretreated population

**Organ Function:**
- May be more lenient given lack of alternatives
- Adequate bone marrow despite prior therapies

**Brain Metastases:**
- More permissive policies
- Stable brain metastases commonly allowed

================================================================================
## CANCER TYPE-SPECIFIC ELIGIBILITY PATTERNS
================================================================================

### LUNG CANCER (NSCLC) TRIALS
================================================================================

**Common Inclusion Criteria:**

**Histology Requirements:**
- Non-squamous vs squamous specification
- Adenocarcinoma subtype (common for targeted therapy trials)

**Biomarker Testing Required:**
- EGFR mutation status (exon 19 del, L858R, T790M, exon 20)
- ALK rearrangement status
- ROS1, BRAF, NTRK, MET, RET alterations (increasingly)
- PD-L1 expression (TPS or CPS)

**Performance Status:**
- ECOG 0-1 (standard)
- ECOG 2 allowed in some later-line trials

**Brain Metastases:**
- Very common in NSCLC (~30-40% at diagnosis)
- Most trials NOW allow treated, stable brain mets
- Targeted therapy trials: More permissive
- Chemotherapy trials: More restrictive

**Prior Therapy Patterns:**
- 1st line: Treatment-naive
- 2nd line: Progression on platinum doublet OR EGFR/ALK TKI
- TKI trials: May require specific prior TKI (e.g., "1st/2nd gen EGFR TKI")

**Common Exclusions:**
- Active malignant pleural/pericardial effusion requiring drainage
- Interstitial lung disease (ILD) - for TKI trials
- Symptomatic brain metastases requiring steroids

### BREAST CANCER TRIALS
================================================================================

**Subtype-Specific Requirements:**

**HR+/HER2- Trials:**
- Postmenopausal status OR premenopausal + ovarian suppression
- Prior endocrine therapy required (for later lines)
- Progression on CDK4/6 inhibitor (for newer trials)
- Visceral crisis exclusion

**HER2+ Trials:**
- HER2 3+ by IHC or ISH amplification required
- Prior trastuzumab exposure (for 2nd line+)
- LVEF ≥50% required (cardiac monitoring)
- Prior anthracycline exposure documentation

**Triple-Negative (TNBC) Trials:**
- HR <1%, HER2- confirmed
- BRCA1/2 mutation testing (increasingly required)
- PD-L1 testing (for immunotherapy combinations)
- Rapid progression common - shorter washout periods

**Common Patterns:**
- Measurable disease OR bone-only disease (if evaluable)
- Prior lines: Varies widely (neoadjuvant, adjuvant, metastatic)
- Brain metastases: Increasingly allowed if stable
- Performance status: ECOG 0-2 more common than other solid tumors

### COLORECTAL CANCER (CRC) TRIALS
================================================================================

**Molecular Testing Requirements:**

**RAS/RAF Testing:**
- KRAS exon 2, 3, 4 (codons 12, 13, 59, 61, 117, 146)
- NRAS mutations
- BRAF V600E mutation
- Required for anti-EGFR therapy trials

**MSI/dMMR Testing:**
- MSI-H or dMMR status
- Critical for immunotherapy trials

**HER2 Amplification:**
- Emerging biomarker (~3% of RAS/BRAF WT CRC)
- Targeted therapy trials

**Prior Therapy Patterns:**
- 1st line: FOLFOX or FOLFIRI ± bevacizumab/anti-EGFR
- 2nd line: Alternative chemotherapy backbone
- 3rd line: Regorafenib, TAS-102 (refractory setting)

**Sidedness Matters:**
- Left-sided vs right-sided colon
- Stratification factor in many trials
- Right-sided less responsive to anti-EGFR

**Common Exclusions:**
- Prior anti-EGFR therapy (for anti-EGFR trials)
- Unresolved bowel obstruction
- Active inflammatory bowel disease

### MELANOMA TRIALS
================================================================================

**Biomarker Requirements:**

**BRAF V600 Mutation:**
- V600E or V600K variants
- Required for BRAF/MEK inhibitor trials

**PD-L1 Status:**
- Less commonly required (melanoma generally immunogenic)

**Prior Therapy Patterns:**
- Adjuvant setting: High-risk resected melanoma
- Metastatic 1st line: Often comparing immunotherapy vs targeted therapy
- Post-immunotherapy: BRAF/MEK inhibitors
- Post-targeted therapy: Immunotherapy

**Brain Metastases:**
- VERY common in melanoma (~50% develop brain mets)
- Most trials allow asymptomatic brain metastases
- Active brain metastases: Some trials specifically include (brain-penetrant drugs)

**Performance Status:**
- ECOG 0-1 standard
- ECOG 2 with brain metastases sometimes allowed

**LDH Levels:**
- Often stratification factor
- Elevated LDH = worse prognosis

### OVARIAN CANCER TRIALS
================================================================================

**Histology Specifications:**
- High-grade serous most common
- Clear cell, endometrioid, mucinous (less common, may be excluded)
- Primary peritoneal and fallopian tube cancers often included

**Platinum Sensitivity Status (Critical):**
- Platinum-sensitive: Recurrence >6 months after platinum
- Platinum-resistant: Recurrence <6 months after platinum
- Platinum-refractory: Progression during platinum therapy
- Determines trial eligibility significantly

**BRCA1/2 Testing:**
- Germline and somatic testing
- Required for PARP inhibitor trials
- Maintenance therapy trials

**HRD (Homologous Recombination Deficiency):**
- Broader than BRCA alone
- Includes BRCA1/2, RAD51C, PALB2, etc.
- Genomic instability score

**Prior Therapy Patterns:**
- 1st line: Platinum/taxane ± bevacizumab
- Maintenance: PARP inhibitors (BRCA/HRD+)
- Recurrent: Depends on platinum-free interval

**CA-125 Monitoring:**
- GCIG CA-125 criteria for progression
- Baseline CA-125 required

### PROSTATE CANCER TRIALS
================================================================================

**Disease Setting:**

**Castration-Resistant Prostate Cancer (CRPC):**
- Testosterone <50 ng/dL despite ADT
- PSA progression OR radiographic progression
- mCRPC: Metastatic CRPC

**Hormone-Sensitive Prostate Cancer (HSPC):**
- Newly diagnosed metastatic disease
- ADT-naive or ADT-responsive

**Biomarker Testing:**
- HRR gene mutations (BRCA1/2, ATM, PALB2, etc.) - for PARP inhibitors
- AR-V7 splice variant (emerging)
- MMR deficiency/MSI-H

**Prior Therapy Requirements:**
- Post-abiraterone or enzalutamide (for CRPC trials)
- Post-docetaxel (for later-line trials)
- No prior AR inhibitor (for 1st-line CRPC)

**PSA Requirements:**
- Baseline PSA ≥2 ng/mL (common threshold)
- PSA doubling time <10 months (aggressive disease)

**Bone Metastases:**
- Very common (~90% of mCRPC)
- Bone scan required at baseline
- DEXA scan (bone health monitoring)

**Pain Status:**
- Asymptomatic/minimally symptomatic vs symptomatic
- Stratification factor

### CERVICAL CANCER TRIALS
================================================================================

**Histology:**
- Squamous cell carcinoma (most common ~75%)
- Adenocarcinoma (~20%)
- Adenosquamous (~5%)

**HPV Status:**
- HPV-16, HPV-18 most common (oncogenic types)
- HPV testing increasingly required
- p16 IHC as surrogate

**Biomarker Testing:**
- PD-L1 CPS (for pembrolizumab eligibility)
- PIK3CA mutations (~15-30% of cervical cancers)
- MSI-H/dMMR (rare in cervical, <5%)

**Disease Setting:**
- Locally advanced (Stage IB2-IVA): Concurrent chemoradiation trials
- Recurrent or metastatic: Systemic therapy trials

**Prior Therapy Patterns:**
- 1st line recurrent/metastatic: Platinum + paclitaxel ± bevacizumab ± pembrolizumab
- 2nd line: Single-agent chemotherapy or immunotherapy

**Performance Status:**
- ECOG 0-1 standard
- ECOG 2 sometimes in later-line

**Common Exclusions:**
- Active pelvic infection
- Rectovaginal or vesicovaginal fistula
- Bowel obstruction

================================================================================
## SPECIAL POPULATION ELIGIBILITY CONSIDERATIONS
================================================================================

### BRAIN METASTASES - EVOLVING LANDSCAPE
================================================================================

**Historical Approach (EXCLUDED):**
- Brain metastases were blanket exclusion
- Concern about CNS progression confounding systemic response

**Current Approach (INCREASINGLY INCLUDED):**

**Criteria for Inclusion:**
- Asymptomatic brain metastases
- Treated (surgery or radiation) and stable on imaging
- No new/enlarging lesions for ≥4 weeks
- Steroid dose ≤10 mg prednisone equivalent daily OR off steroids
- No leptomeningeal disease

**Disease-Specific Permissiveness:**
- NSCLC: Most trials now allow brain mets (common presentation)
- Melanoma: Brain mets very common, trials increasingly inclusive
- Breast cancer: HER2+ trials commonly allow (trastuzumab deruxtecan, tucatinib)
- RCC: Often allowed
- Other solid tumors: Case-by-case

**Brain-Specific Trials:**
- Primary endpoint: Intracranial response
- May specifically REQUIRE brain metastases
- CNS-penetrant agents

### OLDER ADULTS (≥65-70 years)
================================================================================

**General Principles:**
- No upper age limit in most modern trials
- Fitness more important than chronological age

**Special Considerations:**
- Organ function may be borderline (creatinine clearance)
- Comorbidities more common
- Polypharmacy considerations
- Geriatric assessment tools (G8, CARG)

**Trials Specifically for Older Adults:**
- "Fit" vs "unfit" vs "frail" categorization
- Dose-reduced regimens
- Supportive care emphasis

### ECOG PERFORMANCE STATUS 2
================================================================================

**Increasing Recognition:**
- ECOG 2 patients often excluded historically
- Real-world population includes many PS 2 patients

**Trials Including ECOG 2:**
- Later-line trials (3rd line+)
- Palliative intent trials
- Immunotherapy trials (potential for durable benefit)
- Oral targeted therapy trials

**Considerations:**
- Higher toxicity risk
- Lower completion rates
- Survival outcomes worse
- May need dose modifications

### HEPATIC IMPAIRMENT
================================================================================

**Child-Pugh Classification:**
- Class A: Most trials allow
- Class B: Often excluded, some PK studies include
- Class C: Excluded

**Hepatocellular Carcinoma Trials:**
- Liver dysfunction expected
- Modified eligibility criteria
- Bilirubin <3 mg/dL common threshold
- Albumin >2.8 g/dL
- INR <2.3 or PT <6 seconds prolonged

### RENAL IMPAIRMENT
================================================================================

**Creatinine Clearance Thresholds:**
- CrCl ≥60 mL/min: No restrictions
- CrCl 30-60 mL/min: Many trials allow, dose adjustments may apply
- CrCl <30 mL/min: Often excluded
- Dialysis: Usually excluded (some exceptions)

**Renal Cell Carcinoma Trials:**
- Nephrectomy common (reduced renal function)
- CrCl ≥30 mL/min often acceptable

================================================================================
## EXCLUSION CRITERIA PATTERNS
================================================================================

### NEARLY UNIVERSAL EXCLUSIONS
================================================================================

1. **Pregnancy and Nursing:**
   - All oncology trials exclude
   - Contraception required during trial and 3-6 months after

2. **Active Second Malignancy:**
   - Exception: Adequately treated basal/squamous cell skin cancer
   - Exception: In situ cervical cancer
   - Exception: Prior malignancy in remission >2-5 years

3. **Active Uncontrolled Infection:**
   - Requiring IV antibiotics
   - HIV+ patients: Increasingly allowed if undetectable viral load, CD4 >350
   - HBV/HCV: Depends on viral load and liver function

4. **Uncontrolled Intercurrent Illness:**
   - Unstable angina, recent MI (within 3-6 months)
   - Uncontrolled hypertension (BP >160/100 despite medication)
   - Uncontrolled diabetes (HbA1c >8-9%)
   - Psychiatric illness limiting informed consent

5. **Prior Severe Allergic Reaction:**
   - To study drug or excipients
   - Prior anaphylaxis

### IMMUNOTHERAPY-SPECIFIC EXCLUSIONS
================================================================================

**Autoimmune Disease:**
- Active autoimmune disease requiring systemic treatment
- Exception: Vitiligo, controlled hypothyroidism, Type 1 DM on insulin
- Exception: Inactive IBD, resolved childhood asthma

**Immunosuppression:**
- Chronic corticosteroids >10 mg prednisone equivalent
- Other immunosuppressive medications
- Exception: Steroids for adrenal insufficiency, brain metastases

**Organ Transplant:**
- Solid organ transplant (risk of rejection)
- Allogeneic stem cell transplant

**Pneumonitis History:**
- Prior drug-induced pneumonitis
- Active interstitial lung disease

**Neurologic Autoimmune Disease:**
- Myasthenia gravis
- Guillain-Barré syndrome
- Autoimmune neuropathy

### CARDIAC EXCLUSIONS (Drug-Dependent)
================================================================================

**For Cardiotoxic Agents (HER2 inhibitors, anthracyclines):**
- LVEF <50% (or <institutional LLN)
- Prior anthracycline at max cumulative dose
- Recent MI (within 6 months)
- NYHA Class III-IV heart failure

**For QT-Prolonging Agents:**
- Baseline QTc >470-480 ms
- History of torsades de pointes
- Concomitant QT-prolonging medications
- Uncorrected electrolyte abnormalities (K+, Mg2+, Ca2+)

### BLEEDING RISK (Antiangiogenic Agents, Bevacizumab)
================================================================================

**Exclusions:**
- Recent hemoptysis (>1/2 teaspoon within 8 weeks)
- Active GI bleeding
- CNS bleeding within 6 months
- Therapeutic anticoagulation (trial-dependent)
- Recent surgery within 28 days
- Non-healing wound, ulcer, or fracture

================================================================================
## WASHOUT PERIODS BEFORE TRIAL ENROLLMENT
================================================================================

**Chemotherapy:**
- Standard cytotoxics: 3-4 weeks
- Nitrosoureas: 6 weeks
- Mitomycin C: 6 weeks

**Targeted Therapy:**
- Small molecule inhibitors: 2 weeks (or 5 half-lives)
- Monoclonal antibodies: 4 weeks

**Immunotherapy:**
- Checkpoint inhibitors: 4 weeks

**Radiation Therapy:**
- 2-4 weeks (depends on site and field size)
- Palliative radiation to non-target lesion: May be allowed concurrently

**Investigational Agents:**
- 4 weeks or 5 half-lives, whichever is shorter

**Major Surgery:**
- 4 weeks (trial-dependent)

================================================================================
## SUMMARY: KEY PREDICTIVE FACTORS FOR TRIAL ELIGIBILITY
================================================================================

1. **Performance Status:** Single most important factor
2. **Organ Function:** Bone marrow, liver, kidney adequacy
3. **Prior Therapy Lines:** Matches trial design (1st, 2nd, 3rd+ line)
4. **Biomarker Status:** Increasingly required for enrollment
5. **Brain Metastases Status:** Treated and stable often acceptable now
6. **Disease Measurability:** Required for response-based trials
7. **Comorbidities:** Controlled vs uncontrolled critical distinction
8. **Specific Exclusions:** Drug class-specific (cardiac, autoimmune, etc.)

This document serves as a comprehensive reference for predicting trial eligibility
based on patient characteristics and trial design patterns.
